New triple therapy aims to wipe out mantle cell lymphoma
NCT ID NCT07257510
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs—pomalidomide, orelabrutinib, and zuberitamab—in people with untreated mantle cell lymphoma, a type of blood cancer. The goal is to see if the treatment can reduce cancer cells to undetectable levels after six cycles. Participants who achieve this will continue on two of the drugs for maintenance. The trial is currently recruiting 34 patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pomalidomide, orelabrutinib, and zuberitamab
What this could lead to
If successful, this combination could offer a new, effective first-line treatment for mantle cell lymphoma that helps patients achieve undetectable cancer levels.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to control the cancer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••